Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Revenue (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Revenue for 15 consecutive years, with $1.4 million as the latest value for Q3 2025.

  • On a quarterly basis, Revenue fell 6.87% to $1.4 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.3 million, a 8.86% decrease, with the full-year FY2024 number at $5.8 million, up 18.54% from a year prior.
  • Revenue was $1.4 million for Q3 2025 at Plus Therapeutics, up from $1.4 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $1.9 million in Q2 2023 to a low of -$229000.0 in Q2 2021.
  • A 5-year average of $887750.0 and a median of $1.2 million in 2023 define the central range for Revenue.
  • Peak YoY movement for Revenue: soared 1543.84% in 2023, then plummeted 36.85% in 2025.
  • Plus Therapeutics' Revenue stood at -$200000.0 in 2021, then soared by 163.5% to $127000.0 in 2022, then surged by 933.86% to $1.3 million in 2023, then grew by 7.54% to $1.4 million in 2024, then dropped by 1.06% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for PSTV's Revenue are $1.4 million (Q3 2025), $1.4 million (Q2 2025), and $1.1 million (Q1 2025).